(Reuters) – PTC Therapeutics has entered into a licensing deal with a unit of Novartis AG for up to $1.9 billion, the company said on Monday, for its experimental drug being developed for a rare neurological disorder.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila)
